Cara Therapeutics Inc (NASDAQ:CARA) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for shares of Cara Therapeutics in a note issued to investors on Wednesday, March 13th. Jefferies Financial Group analyst C. Howerton forecasts that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter. Jefferies Financial Group has a “Buy” rating and a $22.00 price objective on the stock. Jefferies Financial Group also issued estimates for Cara Therapeutics’ Q2 2019 earnings at ($0.44) EPS, FY2019 earnings at ($1.94) EPS, FY2020 earnings at ($2.12) EPS, FY2021 earnings at ($1.96) EPS, FY2022 earnings at ($0.13) EPS and FY2023 earnings at $1.19 EPS.
A number of other research firms also recently commented on CARA. Bank of America began coverage on Cara Therapeutics in a report on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 target price for the company. Laidlaw set a $30.00 price target on shares of Cara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 20th. Zacks Investment Research upgraded shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a report on Friday, February 8th. HC Wainwright set a $30.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Finally, Janney Montgomery Scott initiated coverage on shares of Cara Therapeutics in a report on Thursday, December 20th. They set a “buy” rating and a $13.36 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $24.03.
Shares of CARA stock opened at $18.95 on Friday. Cara Therapeutics has a 1-year low of $11.46 and a 1-year high of $24.30. The firm has a market cap of $684.83 million, a P/E ratio of -9.20 and a beta of 2.68.
Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.07. The business had revenue of $5.53 million for the quarter, compared to analysts’ expectations of $3.35 million.
In related news, CEO Derek T. Chalmers sold 20,000 shares of the stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $13.61, for a total value of $272,200.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Derek T. Chalmers sold 15,825 shares of the stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $12.53, for a total transaction of $198,287.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 128,942 shares of company stock valued at $1,871,450. Company insiders own 6.70% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund grew its position in shares of Cara Therapeutics by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 30,700 shares of the biopharmaceutical company’s stock valued at $399,000 after purchasing an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Cara Therapeutics by 36.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 964 shares in the last quarter. Avondale Wealth Management raised its position in shares of Cara Therapeutics by 50.0% during the 4th quarter. Avondale Wealth Management now owns 3,000 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,000 shares during the last quarter. California Public Employees Retirement System lifted its stake in Cara Therapeutics by 1.4% in the 4th quarter. California Public Employees Retirement System now owns 86,798 shares of the biopharmaceutical company’s stock valued at $1,128,000 after buying an additional 1,198 shares in the last quarter. Finally, Captrust Financial Advisors lifted its stake in Cara Therapeutics by 40.0% in the 4th quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,400 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
See Also: What is a stock buyback?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.